Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119019 | 0.89 | LIPG (0.33) | DYRK1ALIPGLIPCMTNR1AMTNR1B | |
| SCHEMBL4131197 | 0.88 | DYRK1A (0.33) | DYRK1ALIPGLIPCGSK3BCYP1A2 | |
| SCHEMBL4125114 | 0.87 | NPC1 (0.32) | DYRK1ALIPGLIPCMTNR1AMTNR1B | |
| SCHEMBL3799055 | 0.86 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2RAB9ACYP2D6GAA | |
| SCHEMBL3652325 | 0.86 | NPC1 (0.34) | DYRK1AMTNR1AMTNR1BSMN1; SMN2RAB9A | |
| SCHEMBL4130804 | 0.85 | MGAM (0.35) | DYRK1AGSK3BSMN1; SMN2RAB9AGAA | |
| SCHEMBL4120668 | 0.84 | GSK3B (0.39) | MTNR1AMTNR1BGSK3B | |
| SCHEMBL4132224 | 0.83 | DYRK1A (0.34) | DYRK1AGSK3BCYP1A2CHRM4CYP2D6 | |
| SCHEMBL4135881 | 0.83 | ICAM1 (0.35) | DYRK1ALIPGLIPCGSK3BALDH1A1 | |
| SCHEMBL4130279 | 0.82 | MAPT (0.37) | DYRK1AALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | DYRK1A 4742/4885LIPG 2467/4885LIPC 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.